Cite
HARVARD Citation
Mease, P. et al. (n.d.). OP0216 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial. Annals of the rheumatic diseases. pp. 141-142. [Online].